1.83Open1.73Pre Close1 Volume14 Open Interest8.00Strike Price183.00Turnover7794.11%IV4.93%PremiumAug 16, 2024Expiry Date1.51Intrinsic Value100Multiplier-1DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.5436Delta0.1118Gamma2.68Leverage Ratio-40.1306Theta0.0000Rho-1.45Eff Leverage0.0002Vega
Altimmune Stock Discussion
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet